HF
DNLI icon

HRT Financial’s Denali Therapeutics DNLI Stock Holding History

HRT Financial’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-78,352
Closed -$1.29M – 3984
2025
Q4 		$1.29M Buy
+78,352
New +$1.32M ﹤0.01% 1568
2024
Q4 		– Sell
-16,943
Closed -$493K – 2581
2024
Q3 		$493K Buy
+16,943
New +$420K ﹤0.01% 1596
2024
Q1 		– Sell
-44,292
Closed -$950K – 2477
2023
Q4 		$950K Buy
44,292
+32,087
+263% +$636K 0.01% 1014
2023
Q3 		$251K Buy
+12,205
New +$310K ﹤0.01% 1737
2022
Q4 		– Sell
-77,628
Closed -$2.38M – 2598
2022
Q3 		$2.38M Buy
77,628
+54,028
+229% +$1.76M 0.03% 542
2022
Q2 		$694K Buy
+23,600
New +$618K 0.01% 1256

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

HRT Financial's DNLI Position: Q1 2026 in Review

HRT Financial sold out of Denali Therapeutics (DNLI) in Q1 2026, closing a stake of 78,352 shares — an estimated $1.29M sold.

HRT Financial first reported a position in DNLI in Q2 2022 and held it in 6 quarters. The position peaked at $2.38M in Q3 2022. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • HRT Financial reported no remaining Denali Therapeutics position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 78,352 Denali Therapeutics shares in Q1 2026, an estimated $1.29M.
  • HRT Financial first reported a position in Denali Therapeutics in Q2 2022 and held it in 6 quarters.
  • HRT Financial's Denali Therapeutics position peaked at $2.38M in Q3 2022.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.